The antibody development platform established by our company possesses independent intellectual property rights, which, like a rich mineral deposit, contains large-capacity, diversified 10¹¹ fully-humanized phage display antibody library and the 10¹⁰ synthetic nanobody library. This platform can satisfy the development needs of antibodies and CAR T-cell drugs for different indications. A series of high-affinity fully-humanized antibody drug candidate molecules, such as anti-BCMA, GPC-3, PD-L1, IL-17, and 4-1BB antibodies and ScFv- and VH-based CAR-T cells with synergistic effects have been successfully developed.

There are two major development strategies for our antibody platform. One is to provide targets with a good synergistic effect for CAR-T products, enhancing competitive advantages enjoyed by the company's CAR-T products; the other is to further develop suitable CAR-T targets into antibody drug candidates, so as to yield profits and increase the value of the company through the authorization or cooperative development.

We have constructed a novel and exclusively unique signal activation domain element Ori. After being inserted into the Next Generation CAR structure, it can increase the expansion efficiency of memory immune cells by several folds, effectively breaking through the physical barriers of the extracellular matrix in TME, resisting the immunosuppressive tumor microenvironment, significantly enhancing the anti-tumor activity and durability of CAR T-cells in vivo, and preventing recurrence. In addition, low-dose administration is allowed for CAR T-cell therapy involving a high proportion of memory T cells, which further reduces the safety risk caused by the drug itself.

We have achieved full application of the automated closed-type production process, which effectively reduces the production and preparation costs and improves the affordability of the medications for patients.

OriCell Therapeutics Ori^®TIL: This fast-expansion cell culture technology platform utilizes three major technical tools to break through the bottlenecks, including the difficulty in in vitro TIL expansion, lack of specific tumor residue detection method, and high preparation costs;

The tumor-killing activity and purity of young TIL cells have been enhanced. The tissue-resident memory T cells (TRM) are strengthened with a shortening of the cell culture cycle, thereby ensuring their effectiveness in clinical use;

A general-purpose new detection method has been developed to enable detections below the lower limit. The product has definite components and controllable quality of T-cells, thereby ensuring the safety of reinfusion preparations;

A closed-type production system is utilized, thereby reducing the average preparation costs related to reagent consumables (culture media and cell factors), equipment, personnel, and venues. In this way, we can improve the affordability of clinical treatment.